Trials / Completed
CompletedNCT05232175
Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer
A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 290 (actual)
- Sponsor
- Alteogen, Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALT-BB4 | Recombinant Hyaluronidase |
| DRUG | 0.9%NaCl | Normal Saline |
Timeline
- Start date
- 2022-01-18
- Primary completion
- 2022-08-24
- Completion
- 2022-08-24
- First posted
- 2022-02-09
- Last updated
- 2026-01-29
- Results posted
- 2026-01-29
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05232175. Inclusion in this directory is not an endorsement.